A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer (OTT 10-06)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01545882
Recruitment Status : Terminated (Negative study; Principal Investigator chose to prematurely terminate the study.)
First Posted : March 7, 2012
Last Update Posted : July 23, 2013
Information provided by (Responsible Party):
Ottawa Hospital Research Institute

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Primary Completion Date : October 2011
  Study Completion Date : July 2013